Acura Pharmaceuticals Inc. (NASDAQ:ACUR)

CAPS Rating: 3 out of 5

A pharmaceutical company engaged in research, development and manufacture of innovative Aversion(r) Technology and related product candidates.

Recs

3
Player Avatar zzlangerhans (99.77) Submitted: 10/10/2013 10:03:36 PM : Underperform Start Price: $2.15 ACUR Score: +22.58

Sadly, the best short ideas are often torpedoed by share unavailability or high borrowing costs. Such was the case with Acura, whose umpteenth price spike on a non-catalyst proved unshortable at either of my brokerages. I have to confess I can't understand the phenomenon - I've never been unable to buy shares of a stock, no matter how undervalued Seeking Alpha authors claim it to be, so why can't I short shares of a stock once it begins to "realize its true potential"? Rigged game, perhaps?

I couldn't even bring myself to go over the details of Acura's PR today. Apparently they've managed to ward off generic competition for Oxecta, the drug from which they recognized one thousand dollars in revenue last quarter. Thank god they managed to protect that income stream. The only question about Acura that piques my interest is "will this charade go on forever"?

Featured Broker Partners


Advertisement